Participant‐reported pain relief of 50% or greater · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher self‐reported pain relief of 50% or greater compared with placebo (low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher patient Global Impression to be much or very much improved (PGIC) compared with placebo (low certainty).
1 finding from 1 review
Fatigue · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported fatigue (20‐100 scale) Higher scores indicate higher… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported sleep problems (0‐100 scale) Higher scores indicate… compared with placebo (low certainty).
1 finding from 1 review
Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported health‐related quality of life (0‐100 scale) Higher… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher tolerability (withdrawal due to adverse events) compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · patients with fibromyalgia
It is very uncertain whether serotonin noradrenaline reuptake inhibitors changes safety (serious adverse events) compared with placebo (very low certainty).
1 finding from 1 review
Pain‐free response at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Pain‐free response at 2 h for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Headache relief at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained pain‐free during the 24 h post dose for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained headache relief during the 24 h post dose for moderate or severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
At least 1 AE during treatment for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious AE (all levels of baseline pain) · adults with migraine headache ‐ moderate or severe and mild baseline pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of acute mountain sickness · participants at risk of high altitude illness
Sumatriptan may leads to lower risk of acute mountain sickness compared with placebo (low certainty).
1 finding from 1 review
Risk of high altitude pulmonary oedema · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of high altitude cerebral oedema · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found